Purchase Advances UBC Services in Cognitive Testing
United BioSource Corporation (UBC; Bethesda, MD) announced the aquisition of Cognitive Drug Research (CDR), whose automative cognitive assessment system is the most popular system of its kind in the world. It's been used in more than 1000 clinical trials, encompasses 50 different disease areas, and is validated in over 60 languages. In addition, CDR maintains the industry’s largest healthy subject, drug, and patient databases of cognitive effects.
“The premier evidence base, reliability, and global reach of the CDR System coupled with UBC’s validated rater training, assessment, and rater surveillance methods will provide an unprecedented opportunity for improved signal detection in the measurement of cognition and clinically subjective endpoints,” said Ethan Leder, Chief Exectuive Officer of UBC, in a company press release. “The addition of Professor Keith Wesnes, to the UBC scientific team and our integrated offerings will provide sponsor companies with the broadest, most seamless capabilities available.”
Professor Keith Wesnes founded CDR in 1986.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
